Journal Cover
The Lancet
Journal Prestige (SJR): 14.934
Citation Impact (citeScore): 9
Number of Followers: 2824  
 
  Full-text available via subscription Subscription journal
ISSN (Print) 0140-6736 - ISSN (Online) 1474-547X
Published by Elsevier Homepage  [3177 journals]
  • Prioritising people with disabilities implies furthering rehabilitation
    • Abstract: Publication date: Available online 2 December 2019Source: The LancetAuthor(s): Stefano Negrini, Carlotte Kiekens, Allen W Heinemann, Levent Özçakar, Walter R Frontera
       
  • The complex challenges of HIV vaccine development require renewed and
           expanded global commitment
    • Abstract: Publication date: Available online 2 December 2019Source: The LancetAuthor(s): Linda-Gail Bekker, Roger Tatoud, Francois Dabis, Mark Feinberg, Pontiano Kaleebu, Mary Marovich, Thumbi Ndung'u, Nina Russell, Jeremiah Johnson, Maureen Luba, Anthony S Fauci, Lynn Morris, Giuseppe Pantaleo, Susan Buchbinder, Glenda Gray, Johan Vekemans, Jerome H Kim, Yves Levy, Lawrence Corey, Robin Shattock
       
  • Stigma, politics, and an epidemic: HIV in the Philippines
    • Abstract: Publication date: Available online 30 November 2019Source: The LancetAuthor(s): Sharmila Devi
       
  • Dolutegravir: advancing ethical research in pregnancy
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): Anne Drapkin Lyerly
       
  • Muscular dystrophies
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): Eugenio Mercuri, Carsten G Bönnemann, Francesco MuntoniSummaryMuscular dystrophies are primary diseases of muscle due to mutations in more than 40 genes, which result in dystrophic changes on muscle biopsy. Now that most of the genes responsible for these conditions have been identified, it is possible to accurately diagnose them and implement subtype-specific anticipatory care, as complications such as cardiac and respiratory muscle involvement vary greatly. This development and advances in the field of supportive medicine have changed the standard of care, with an overall improvement in the clinical course, survival, and quality of life of affected individuals. The improved understanding of the pathogenesis of these diseases is being used for the development of novel therapies. In the most common form, Duchenne muscular dystrophy, a few personalised therapies have recently achieved conditional approval and many more are at advanced stages of clinical development. In this Seminar, we concentrate on clinical manifestations, molecular pathogenesis, diagnostic strategy, and therapeutic developments for this group of conditions.
       
  • Brazil's health-care system
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): Maria Laura Orlandi Demo, Larissa Chaiane Orth, Chaiana Esmeraldino Mendes Marcon
       
  • Youth activists for our health
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): Jan Skrzypczak, Benedikt W Pelzer, Orsolya Süli
       
  • The harsh effects of sanctions on Iranian health
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): Payman Salamati, Claudia Chaufan
       
  • Clinical outcomes after ABO-incompatible renal transplantation –
           Authors' reply
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): Florian Gunnar Scurt, Peter René Mertens, Christos Chatzikyrkou
       
  • Clinical outcomes after ABO-incompatible renal transplantation
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): Christian Morath, Stefan Zschiedrich, Claudius Speer, Martin Zeier, Bernd Döhler, Gerhard Opelz, Caner Süsal
       
  • Clinical outcomes after ABO-incompatible renal transplantation
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): Alexandre Loupy, Antoine Bouquegneau, Mark D Stegall, Robert A Montgomery
       
  • Global health, human rights, and the law – Authors' reply
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): Lawrence O Gostin, John T Monahan, Jenny Kaldor, Eric A Friedman
       
  • Global health, human rights, and the law
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): Leonard S Rubenstein, Joseph J Amon
       
  • Global health, human rights, and the law
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): Lisa Forman, Claire E Brolan, Kristi Heather Kenyon
       
  • Sadako Ogata
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): Andrew Green
       
  • Truth and torture in the war on terror
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): George J Annas
       
  • Image irregularities found in prominent scientist's papers
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): Brian Owens
       
  • Will Trump snuff out e-cigarettes'
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): Susan Jaffe
       
  • Offline: It's time to prepare your anti-CV
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): Richard Horton
       
  • Muscular dystrophy: new treatments, new hopes
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): The Lancet
       
  • The unfolding migrant crisis in Latin America
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): The Lancet
       
  • Research integrity: time for global action
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): The Lancet
       
  • Now you see it: progressive radiographic findings in avascular necrosis of
           the hip
    • Abstract: Publication date: 30 November–6 December 2019Source: The Lancet, Volume 394, Issue 10213Author(s): Paul Stirling, Matthew Moran
       
  • Inside Ukrainian social care homes
    • Abstract: Publication date: Available online 29 November 2019Source: The LancetAuthor(s): Rob Keukens, Norman Sartorius, Graham Thornicroft, Robert van Voren
       
  • Tensions grow between Hong Kong police and medics
    • Abstract: Publication date: Available online 29 November 2019Source: The LancetAuthor(s): Shawn Yuan
       
  • Moving beyond cytotoxic drug dosing in ovarian cancer
    • Abstract: Publication date: Available online 29 November 2019Source: The LancetAuthor(s): Ramez N Eskander, Bradley J Monk
       
  • Unacceptable failures: the final report of the Lancet Commission into
           liver disease in the UK
    • Abstract: Publication date: Available online 29 November 2019Source: The LancetAuthor(s): Roger Williams, Guruprasad Aithal, Graeme J Alexander, Michael Allison, Iain Armstrong, Richard Aspinall, Alastair Baker, Rachel Batterham, Katrina Brown, Robyn Burton, Matthew E Cramp, Natalie Day, Anil Dhawan, Colin Drummond, James Ferguson, Graham Foster, Ian Gilmore, Jonny Greenberg, Clive Henn, Helen JarvisSummaryThis final report of the Lancet Commission into liver disease in the UK stresses the continuing increase in burden of liver disease from excess alcohol consumption and obesity, with high levels of hospital admissions which are worsening in deprived areas. Only with comprehensive food and alcohol strategies based on fiscal and regulatory measures (including a minimum unit price for alcohol, the alcohol duty escalator, and an extension of the sugar levy on food content) can the disease burden be curtailed. Following introduction of minimum unit pricing in Scotland, alcohol sales fell by 3%, with the greatest effect on heavy drinkers of low-cost alcohol products. We also discuss the major contribution of obesity and alcohol to the ten most common cancers as well as measures outlined by the departing Chief Medical Officer to combat rising levels of obesity—the highest of any country in the west. Mortality of severely ill patients with liver disease in district general hospitals is unacceptably high, indicating the need to develop a masterplan for improving hospital care. We propose a plan based around specialist hospital centres that are linked to district general hospitals by operational delivery networks. This plan has received strong backing from the British Association for Study of the Liver and British Society of Gastroenterology, but is held up at NHS England. The value of so-called day-case care bundles to reduce high hospital readmission rates with greater care in the community is described, along with examples of locally derived schemes for the early detection of disease and, in particular, schemes to allow general practitioners to refer patients directly for elastography assessment. New funding arrangements for general practitioners will be required if these proposals are to be taken up more widely around the country. Understanding of the harm to health from lifestyle causes among the general population is low, with a poor knowledge of alcohol consumption and dietary guidelines. The Lancet Commission has serious doubts about whether the initiatives described in the Prevention Green Paper, with the onus placed on the individual based on the use of information technology and the latest in behavioural science, will be effective. We call for greater coordination between official and non-official bodies that have highlighted the unacceptable disease burden from liver disease in England in order to present a single, strong voice to the higher echelons of government.
       
  • Conversations for common humanity: the 2019 Global Health Film Festival
    • Abstract: Publication date: Available online 29 November 2019Source: The LancetAuthor(s): Sophie Harman
       
  • Joint statement on EPA proposed rule and public availability of data
           (2019)
    • Abstract: Publication date: Available online 27 November 2019Source: The LancetAuthor(s): H Holden Thorp, Magdalena Skipper, Veronique Kiermer, May Berenbaum, Deborah Sweet, Richard Horton
       
  • Corruption in global health: the open secret
    • Abstract: Publication date: Available online 27 November 2019Source: The LancetAuthor(s): Patricia J GarcíaSummaryCorruption is embedded in health systems. Throughout my life—as a researcher, public health worker, and a Minister of Health—I have been able to see entrenched dishonesty and fraud. But despite being one of the most important barriers to implementing universal health coverage around the world, corruption is rarely openly discussed. In this Lecture, I outline the magnitude of the problem of corruption, how it started, and what is happening now. I also outline people's fears around the topic, what is needed to address corruption, and the responsibilities of the academic and research communities in all countries, irrespective of their level of economic development. Policy makers, researchers, and funders need to think about corruption as an important area of research in the same way we think about diseases. If we are really aiming to achieve the Sustainable Development Goals and ensure healthy lives for all, corruption in global health must no longer be an open secret.
       
  • Should doctors have a legal duty to warn relatives of their genetic
           risks'
    • Abstract: Publication date: Available online 26 November 2019Source: The LancetAuthor(s): Anna Middleton, Richard Milne, Lauren Robarts, Jonathan Roberts, Christine Patch
       
  • WHO's proposal for a decade of healthy ageing
    • Abstract: Publication date: Available online 26 November 2019Source: The LancetAuthor(s): Peter Lloyd-Sherlock, Alex Kalache, Tom Kirkwood, Martin McKee, Martin Prince
       
  • EATLancet vs yes2meat: the digital backlash to the planetary
           health diet
    • Abstract: Publication date: Available online 25 November 2019Source: The LancetAuthor(s): David Garcia, Victor Galaz, Stefan Daume
       
  • Tore Godal: quiet colossus of global health
    • Abstract: Publication date: Available online 25 November 2019Source: The LancetAuthor(s): Richard Lane
       
  • Ebola virus vaccine receives prequalification
    • Abstract: Publication date: 23–29 November 2019Source: The Lancet, Volume 394, Issue 10212Author(s): Talha Burki
       
  • Acute kidney injury
    • Abstract: Publication date: 23–29 November 2019Source: The Lancet, Volume 394, Issue 10212Author(s): Claudio Ronco, Rinaldo Bellomo, John A KellumSummaryAcute kidney injury (AKI) is defined by a rapid increase in serum creatinine, decrease in urine output, or both. AKI occurs in approximately 10–15% of patients admitted to hospital, while its incidence in intensive care has been reported in more than 50% of patients. Kidney dysfunction or damage can occur over a longer period or follow AKI in a continuum with acute and chronic kidney disease. Biomarkers of kidney injury or stress are new tools for risk assessment and could possibly guide therapy. AKI is not a single disease but rather a loose collection of syndromes as diverse as sepsis, cardiorenal syndrome, and urinary tract obstruction. The approach to a patient with AKI depends on the clinical context and can also vary by resource availability. Although the effectiveness of several widely applied treatments is still controversial, evidence for several interventions, especially when used together, has increased over the past decade.
       
  • Representation of women among scientific Nobel Prize nominees
    • Abstract: Publication date: 23–29 November 2019Source: The Lancet, Volume 394, Issue 10212Author(s): Morteza Mahmoudi, Julie A Poorman, Julie K Silver
       
  • Quantifying the benefit of non-small-cell lung cancer immunotherapy
           – Authors' reply
    • Abstract: Publication date: 23–29 November 2019Source: The Lancet, Volume 394, Issue 10212Author(s): Tony S K Mok, Jin Zhang, Gilberto Lopes
       
  • Quantifying the benefit of non-small-cell lung cancer immunotherapy
    • Abstract: Publication date: 23–29 November 2019Source: The Lancet, Volume 394, Issue 10212Author(s): Ethan B Ludmir, Zachary R McCaw, Aaron J Grossberg, Lee-Jen Wei, C David Fuller
       
  • The life improvement value: a new measure of cost-efficiency
    • Abstract: Publication date: 23–29 November 2019Source: The Lancet, Volume 394, Issue 10212Author(s): Sam Shuster
       
  • WHO's slow progress on transgender and gender diverse health
    • Abstract: Publication date: 23–29 November 2019Source: The Lancet, Volume 394, Issue 10212Author(s): Robbert J Duvivier, Elizabeth Wiley
       
  • Bernard Fisher
    • Abstract: Publication date: 23–29 November 2019Source: The Lancet, Volume 394, Issue 10212Author(s): Geoff Watts
       
  • Mirror fragments
    • Abstract: Publication date: 23–29 November 2019Source: The Lancet, Volume 394, Issue 10212Author(s): Marco De Ambrogi
       
  • A mother bears witness to the conflict in Syria
    • Abstract: Publication date: 23–29 November 2019Source: The Lancet, Volume 394, Issue 10212Author(s): Aarathi Prasad
       
  • 2019 Prince Mahidol Award winners announced
    • Abstract: Publication date: 23–29 November 2019Source: The Lancet, Volume 394, Issue 10212Author(s): Talha Burki
       
  • No clear way ahead: smog in northern India
    • Abstract: Publication date: 23–29 November 2019Source: The Lancet, Volume 394, Issue 10212Author(s): Dinesh C Sharma
       
  • Offline: Why global health must talk about death
    • Abstract: Publication date: 23–29 November 2019Source: The Lancet, Volume 394, Issue 10212Author(s): Richard Horton
       
  • The scale and profile of global dementia research funding
    • Abstract: Publication date: 23–29 November 2019Source: The Lancet, Volume 394, Issue 10212Author(s): James Pickett, Carol Brayne
       
  • Promoting and prescribing the arts for health
    • Abstract: Publication date: 23–29 November 2019Source: The Lancet, Volume 394, Issue 10212Author(s): The Lancet
       
  • Lung cancer: some progress, but still a lot more to do
    • Abstract: Publication date: 23–29 November 2019Source: The Lancet, Volume 394, Issue 10212Author(s): The Lancet
       
  • 2020: unleashing the full potential of nursing
    • Abstract: Publication date: 23–29 November 2019Source: The Lancet, Volume 394, Issue 10212Author(s): The Lancet
       
  • Seeing red degeneration in uterine fibroids in pregnancy: proceed with
           caution
    • Abstract: Publication date: 23–29 November 2019Source: The Lancet, Volume 394, Issue 10212Author(s): Ana Sofia Cerdeira, Mariana Tome, Niall Moore, Lee Lim
       
  • Monitoring the health-related Sustainable Development Goals: lessons
           learned and recommendations for improved measurement
    • Abstract: Publication date: Available online 22 November 2019Source: The LancetAuthor(s): Samira Asma, Rafael Lozano, Somnath Chatterji, Soumya Swaminathan, Maria de Fátima Marinho, Naoko Yamamoto, Elena Varavikova, Awoke Misganaw, Michael Ryan, Lalit Dandona, Ren Minghui, Christopher J L Murray
       
  • Air pollution and chronic airway disease: is the evidence always
           clear'
    • Abstract: Publication date: Available online 21 November 2019Source: The LancetAuthor(s): Peter Burney, André F S Amaral
       
  • The political determinants of health and wellbeing in the Lebanese
           uprising
    • Abstract: Publication date: Available online 21 November 2019Source: The LancetAuthor(s): Iman Nuwayhid, Huda Zurayk
       
  • International humanitarian norms are violated in Hong Kong
    • Abstract: Publication date: Available online 21 November 2019Source: The LancetAuthor(s): Darren Mann
       
  • Integration of Kashmir for peace and prosperity
    • Abstract: Publication date: Available online 4 September 2019Source: The LancetAuthor(s): Mahaveer Golechha
       
  • The first local cases of Zika virus in Europe
    • Abstract: Publication date: Available online 18 November 2019Source: The LancetAuthor(s): Oliver J Brady, Simon I Hay
       
  • Improving NASH with a little help from thyromimetics
    • Abstract: Publication date: Available online 15 November 2019Source: The LancetAuthor(s): Vlad Ratziu
       
  • Incorporating isatuximab in the treatment of multiple myeloma
    • Abstract: Publication date: Available online 14 November 2019Source: The LancetAuthor(s): Suzanne Trudel
       
  • JAK inhibitors: promising for a wider spectrum of autoimmune diseases'
    • Abstract: Publication date: Available online 12 November 2019Source: The LancetAuthor(s): Maria G Tektonidou
       
  • Immunotherapy: a new era in small-cell lung cancer
    • Abstract: Publication date: Available online 4 October 2019Source: The LancetAuthor(s): Thorsten Oliver Goetze
       
  • Launching the Universal Health Coverage Legal Solutions Network
    • Abstract: Publication date: Available online 30 September 2019Source: The LancetAuthor(s): Lawrence O Gostin, Aleksandra Blagojevic, Simon Bland, Mandeep Dhaliwal, Ranieri Guerra, John T Monahan
       
  • Department of Error
    • Abstract: Publication date: Available online 6 September 2019Source: The LancetAuthor(s):
       
  • Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis:
           a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
           
    • Abstract: Publication date: Available online 11 November 2019Source: The LancetAuthor(s): Stephen A Harrison, Mustafa R Bashir, Cynthia D Guy, Rong Zhou, Cynthia A Moylan, Juan P Frias, Naim Alkhouri, Meena B Bansal, Seth Baum, Brent A Neuschwander-Tetri, Rebecca Taub, Sam E MoussaSummaryBackgroundNon-alcoholic steatohepatitis (NASH) is characterised by hepatic steatosis, inflammation, hepatocellular injury, and progressive liver fibrosis. Resmetirom (MGL-3196) is a liver-directed, orally active, selective thyroid hormone receptor-β agonist designed to improve NASH by increasing hepatic fat metabolism and reducing lipotoxicity. We aimed to assess the safety and efficacy of resmetirom in patients with NASH.MethodsMGL-3196-05 was a 36-week randomised, double-blind, placebo-controlled study at 25 centres in the USA. Adults with biopsy confirmed NASH (fibrosis stages 1–3) and hepatic fat fraction of at least 10% at baseline when assessed by MRI-proton density fat fraction (MRI-PDFF) were eligible. Patients were randomly assigned 2:1 by a computer-based system to receive resmetirom 80 mg or matching placebo, orally once a day. Serial hepatic fat measurements were obtained at weeks 12 and 36, and a second liver biopsy was obtained at week 36. The primary endpoint was relative change in MRI-PDFF assessed hepatic fat compared with placebo at week 12 in patients who had both a baseline and week 12 MRI-PDFF. This trial is registered with ClinicalTrials.gov, number NCT02912260.Findings348 patients were screened and 84 were randomly assigned to resmetirom and 41 to placebo at 18 sites in the USA. Resmetirom-treated patients (n=78) showed a relative reduction of hepatic fat compared with placebo (n=38) at week 12 (−32·9% resmetirom vs −10·4% placebo; least squares mean difference −22·5%, 95% CI −32·9 to −12·2; p
       
  • A new short-term treatment option for osteoarthritis'
    • Abstract: Publication date: Available online 11 November 2019Source: The LancetAuthor(s): Graeme Jones, Tania Winzenberg
       
  • Identifying, tracking, and treating lung injury associated with
           e-cigarettes or vaping
    • Abstract: Publication date: Available online 8 November 2019Source: The LancetAuthor(s): Laura E Crotty Alexander, Mario F Perez
       
  • Clinical presentation, treatment, and short-term outcomes of lung injury
           associated with e-cigarettes or vaping: a prospective observational cohort
           study
    • Abstract: Publication date: Available online 8 November 2019Source: The LancetAuthor(s): Denitza P Blagev, Dixie Harris, Angela C Dunn, David W Guidry, Colin K Grissom, Michael J LanspaSummaryBackgroundAn ongoing outbreak of lung injury associated with e-cigarettes or vaping (also known as E-VALI or VALI) started in March, 2019, in the USA. The cause, diagnosis, treatment, and course of this disease remains unknown.MethodsIn this multicentre, prospective, observational, cohort study, we collected data on all patients with lung injury associated with e-cigarettes or vaping seen in Intermountain Healthcare, an integrated health system based in Utah, USA, between June 27 and Oct 4, 2019. Telecritical care, based in Salt Lake City, UT, USA, was used as the central repository for case validation, public reporting, and system-wide dissemination of expertise, which included a proposed diagnosis and treatment guideline for lung injury associated with e-cigarettes or vaping. We extracted data on patient presentation, treatment, and short-term follow-up (2 weeks after discharge) from chart review and interviews with patients undertaken by the Utah Department of Health (Salt Lake City, UT, USA).Findings60 patients presented with lung injury associated with e-cigarettes or vaping at 13 hospitals or outpatient clinics in the integrated health system. 33 (55%) of 60 were admitted to an intensive care unit (ICU). 53 (88%) of 60 patients presented with constitutional symptoms, 59 (98%) with respiratory symptoms, and 54 (90%) with gastrointestinal symptoms. 54 (90%) of 60 were given antibiotics and 57 (95%) were given steroids. Six (10%) of 60 patients were readmitted to an ICU or hospital within 2 weeks, three (50%) of whom had relapsed with vaping or e-cigarette use. Of 26 patients who were followed up within 2 weeks, despite clinical and radiographic improvement in all, many had residual abnormalities on chest radiographs (ten [67%] of 15) and pulmonary function tests (six [67%] of nine). Two patients died and lung injury associated with e-cigarettes or vaping was thought to be a contributing factor, but not the cause of death, for both.InterpretationLung injury associated with e-cigarettes or vaping is an emerging illness associated with severe lung injury and constitutional and gastrointestinal symptoms. Increased awareness has led to identification of a broad spectrum of severity of illness in patients who were treated with antibiotics and steroids. Despite improvement, at short-term follow-up many patients had residual abnormalities. Lung injury associated with e-cigarettes or vaping remains a clinical diagnosis with symptoms that overlap infectious and other lung diseases. Maintaining a high index of suspicion for this disease is important as work continues in understanding the cause or causes, optimal therapy, and long-term outcomes of these patients.FundingIntermountain Healthcare.
       
  • Sharing data safely while preserving privacy
    • Abstract: Publication date: Available online 7 November 2019Source: The LancetAuthor(s): Giske Ursin, Nea Malila, Jenny Chang-Claude, Marc Gunter, Rudolf Kaaks, Ellen Kampman, Mats Lambe, Flora van Leeuwen, Patrik Magnusson, Mef C Nilbert, Pål R Romundstad, Martin Röösli, Anne Lise Ryel, Isabel dos-Santos-Silva, Magnus Stenbeck, Hans H Storm, Anthony Swerdlow, Paolo Vineis, Gun Peggy S Knudsen
       
  • Innovation in valve repair devices
    • Abstract: Publication date: Available online 7 November 2019Source: The LancetAuthor(s): Fadia Tohme-Shaya, Apoorva M Pradhan
       
  • Data must be shared—also with researchers outside of Europe
    • Abstract: Publication date: Available online 7 November 2019Source: The LancetAuthor(s): Giske Ursin, Magnus Stenbeck, Jenny Chang-Claude, Marc Gunter, Rudolf Kaaks, Ellen Kampman, Mats Lambe, Flora van Leeuwen, Patrik Magnusson, Nea Malila, Mef C Nilbert, Pål R Romundstad, Martin Röösli, Anne Lise Ryel, Isabel dos-Santos-Silva, Hans H Storm, Anthony Swerdlow, Paolo Vineis, Gun Peggy S Knudsen
       
  • Protecting the health of children moving to Canada
    • Abstract: Publication date: Available online 6 November 2019Source: The LancetAuthor(s): Taj Jadavji, Raynell Lang, M John Gill
       
  • PD-1 immunotherapy for recurrent or metastatic HNSCC
    • Abstract: Publication date: Available online 1 November 2019Source: The LancetAuthor(s): Robert L Ferris, Lisa Licitra
       
  • Sustainable development levers are key in global response to antimicrobial
           resistance
    • Abstract: Publication date: Available online 31 October 2019Source: The LancetAuthor(s): Angelina Taylor, Jasper Littmann, Anna Holzscheiter, Maike Voss, Lothar Wieler, Tim Eckmanns
       
  • Department of Error
    • Abstract: Publication date: Available online 31 October 2019Source: The LancetAuthor(s):
       
  • Entering the era of highly effective CFTR modulator therapy
    • Abstract: Publication date: Available online 31 October 2019Source: The LancetAuthor(s): Edith T Zemanick, Frank J Accurso
       
  • Deep anaesthesia and poor outcomes: the jury is still out
    • Abstract: Publication date: Available online 20 October 2019Source: The LancetAuthor(s): Helen F Galley, Nigel R Webster
       
  • Department of Error
    • Abstract: Publication date: Available online 7 October 2019Source: The LancetAuthor(s):
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 3.214.184.124
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-